mTOR-activating mutations occur in diffuse large B cell lymphoma (DLBCL),2 and elevated mTORC1 activity correlates with chemotherapy resistance and poor prognosis in pre-B acute lymphoblastic leukaemia (B-ALL).3 The gene discussed is MTOR; the disease is diffuse large B-cell lymphoma.